Callan JMB to Oversee Manufacturing, Quality for Attune Biotech's Long COVID IND Trials
CJMB sits 74% above its 52-week low of $1.082.
Summary
Callan JMB Inc. has been selected to oversee manufacturing and quality control for Attune Biotech's Investigational New Drug (IND) clinical trials for lodonal™ (JKB-122), a drug targeting Long COVID. This engagement includes critical services such as Contract Manufacturing Organization (CMO) qualification, comprehensive batch record review, and supply chain verification. This specific project follows a strategic teaming agreement announced in January 2026, where Callan JMB was established as an independent third-party overseer for Attune's operations. The FDA has received and assigned an IND application number for lodonal™ for Long COVID, a condition with significant unmet medical need. For Callan JMB, a micro-cap company, this represents a concrete revenue-generating contract and a significant validation of its specialized logistics and oversight services within the life sciences sector. Investors will monitor the progress of Attune Biotech's Phase 2b/3 clinical trials for lodonal™ and any further specific engagements or expansions of the partnership.
At the time of this announcement, CJMB was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $1.08 to $6.13. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.